Review
Health Care Sciences & Services
Lindsay Hammons, Timothy S. Fenske
Summary: Mantle cell lymphoma is a clinically heterogenous disease that requires a risk-adapted approach to guide treatment selection.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Review
Hematology
Elisabeth Silkenstedt, Kim Linton, Martin Dreyling
Summary: Mantle cell lymphoma (MCL) exhibits heterogeneous behavior, with treatment options needing to be tailored based on individual risk profiles for optimal outcomes. Recent advances in understanding the molecular background of MCL have led to innovative therapies and improved treatment recommendations for primary and relapsed/refractory MCL.
BRITISH JOURNAL OF HAEMATOLOGY
(2021)
Editorial Material
Hematology
Peter W. M. Johnson
Summary: The study shows that treating relapsed or refractory HL with PD-1 antibody nivolumab has a high response rate, making it an attractive option for second-line therapy.
Article
Hematology
Juan Pablo Alderuccio, Luca Arcaini, Marcus P. Watkins, Anne W. Beaven, Geoffrey Shouse, Narendranath Epperla, Michele Spina, Alexandra Stefanovic, Jose Sandoval-Sus, Pallawi Torka, Ash B. Alpert, Adam J. Olszewski, Seo-Hyun Kim, Brian Hess, Sameh Gaballa, Sabarish Ayyappan, Jorge J. Castillo, Lisa Argnani, Timothy J. Voorhees, Raya Saba, Sayan Mullick Chowdhury, Fernando Vargas, Isildinha M. Reis, Deukwoo Kwon, Jonathan S. Alexander, Wei Zhao, Dali Edwards, Peter Martin, Emanuele Cencini, Manali Kamdar, Brian K. Link, Constantine N. Logothetis, Alex F. Herrera, Jonathan W. Friedberg, Brad S. Kahl, Stefano Luminari, Pier Luigi Zinzani, Izidore S. Lossos
Summary: This study aimed to analyze the frontline treatment of extranodal marginal zone lymphoma (EMZL) patients. The study found that the combination of rituximab with bendamustine (BR) regimen had a highly effective and durable remission in EMZL patients, overcoming adverse prognosis factors. However, during BR treatment, infectious complications such as herpes zoster may occur.
Review
Biochemistry & Molecular Biology
Zoufang Huang, Vivek P. Chavda, Rajashri Bezbaruah, Hemant Dhamne, Dong-Hua Yang, Hong-Bing Zhao
Summary: Mantle cell lymphoma (MCL) is a subtype of Non-Hodgkin lymphoma characterized by translocation of Cyclin D1. Despite progress in understanding the causes and available treatments, MCL remains incurable. CAR-T cell therapy shows potential for treating B-cell malignancies and MCL.
Article
Oncology
Timothy S. Fenske
Summary: The Oncology Grand Rounds series aims to provide clinical context for original reports published in the Journal. This article presents a case of a 73-year-old woman with mantle cell lymphoma (MCL) who achieved remission with bendamustine and rituximab. The relevant literature is reviewed, including prospective clinical trials and large retrospective real-world cohorts. The findings highlight the challenges in frontline treatment selection for MCL patients.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Keman Zhang, Nand K. Roy, Yorleny Vicioso, Janghee Woo, Rose Beck, Marcos de Lima, Paolo Caimi, Daniel Feinberg, Reshmi Parameswaran
Summary: Mantle cell lymphoma (MCL) is an aggressive form of B cell non-Hodgkin's lymphoma that remains incurable under current treatment modalities. Research shows that B cell activating factor (BAFF) and BAFF receptor (BAFF-R) play important roles in the proliferation and survival of MCL cells, with high serum BAFF levels often correlated with poor drug response. Targeting BAFF-R using antibody therapy shows promise in overcoming drug resistance in MCL patients and improving treatment efficacy.
Article
Cell Biology
Sabrina Manni, Maria Pesavento, Zaira Spinello, Lara Saggin, Arash Arjomand, Anna Fregnani, Laura Quotti Tubi, Greta Scapinello, Carmela Gurrieri, Gianpietro Semenzato, Livio Trentin, Francesco Piazza
Summary: CK2 is an overexpressed kinase in many solid and blood-derived tumors. This study demonstrates that CK2 sustains MCL cell proliferation, survival, and anti-apoptotic ability, and is involved in BCR and Bcl-2 related signaling. CK2 inactivation enhances the cytotoxicity of Ibrutinib and Venetoclax, offering a potential strategy to overcome drug resistance.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2022)
Article
Oncology
Sabrina Manni, Anna Fregnani, Laura Quotti Tubi, Zaira Spinello, Marco Carraro, Greta Scapinello, Andrea Visentin, Gregorio Barila, Marco Pizzi, Angelo Paolo Dei Tos, Fabrizio Vianello, Renato Zambello, Carmela Gurrieri, Gianpietro Semenzato, Livio Trentin, Francesco Piazza
Summary: Mantle Cell Lymphoma (MCL) is an incurable B-cell malignancy with poor prognosis. Protein kinase CK1 alpha plays a crucial role in sustaining MCL growth by regulating BCR-related survival signaling cascades. Inhibition of CK1 alpha combined with Ibrutinib or Duvelisib can synergistically increase cytotoxicity and decrease BCR signaling activation in MCL cells.
FRONTIERS IN ONCOLOGY
(2021)
Article
Multidisciplinary Sciences
Gi-June Min, Young-Woo Jeon, Tong Yoon Kim, Daehun Kwag, Byung-Su Kim, Joonyeop Lee, Jong Hyuk Lee, Sung-Soo Park, Silvia Park, Jae-Ho Yoon, Sung-Eun Lee, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Seok Lee, Hee-Je Kim, Chang-Ki Min, Jong Wook Lee, Seok-Goo Cho
Summary: In this study, we analyzed the clinical characteristics and outcomes of 52 patients with relapsed/refractory diffuse large B cell lymphoma treated with allo-HSCT. Overall survival, event-free survival, and graft-versus-host disease-free, relapse-free survival outcomes were significantly better in patients who achieved remission before allo-HSCT. A shorter interval from diagnosis to allo-HSCT was associated with poorer survival and higher relapse rates. Patients with active disease had lower event-free survival and graft-versus-host disease-free, relapse-free survival.
SCIENTIFIC REPORTS
(2023)
Review
Oncology
Meri Tarockoff, Teresita Gonzalez, Stanislav Ivanov, Jose Sandoval-Sus
Summary: This review summarizes the current treatment strategies for R/R MCL, discusses evolving agents, and provides guidance in treating this complex disease. Advancements in targeted therapy, cellular therapies, and novel therapeutic agents show promising results for refractory and relapsed mantle cell lymphoma.
CURRENT ONCOLOGY REPORTS
(2022)
Review
Oncology
Miriam Marangon, Carlo Visco, Anna Maria Barbui, Annalisa Chiappella, Alberto Fabbri, Simone Ferrero, Sara Galimberti, Stefano Luminari, Gerardo Musuraca, Alessandro Re, Vittorio Ruggero Zilioli, Marco Ladetto
Summary: Mantle Cell Lymphoma (MCL) is a rare lymphoproliferative disorder that has been regarded as incurable since its identification. For two decades, allogeneic transplantation has been the only option capable of ensuring prolonged remissions and potential cure. However, its application has been limited by feasibility constraints and significant toxicity, particularly in elderly patients.
Article
Oncology
Colton Ladbury, Swetha Kambhampati, Tamer Othman, Claire Hao, Lu Chen, Jeffrey Wong, Thai Cao, Alex Herrera, Matthew Mei, Savita Dandapani
Summary: Approximately 50% of patients with relapsed/refractory diffuse large B cell lymphoma (R/R DLBCL) will relapse post-autologous stem cell transplant (ASCT). This study investigated the use of radiation therapy (RT) as salvage treatment for these patients. The results showed favorable oncologic outcomes for patients who received RT as first salvage therapy post-ASCT, particularly those with localized disease.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2022)
Editorial Material
Hematology
Rory McCulloch
Summary: In a large retrospective analysis, outcomes of post-BTKi mantle cell lymphoma patients were described, providing a benchmark for future studies and highlighting the challenges in managing this patient cohort.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Oncology
Giulia Bega, Jacopo Olivieri, Marcello Riva, Greta Scapinello, Rossella Paolini, Silvia Finotto, Roberto Sartori, Elisa Lucchini, Gianmarco Guandalini, Davide Facchinelli, Maria Chiara Tisi, Marco Basso, Laura Ballotta, Francesco Piazza, Isacco Ferrarini, Carlo Visco
Summary: Both BR and R-BAC are suitable induction therapies for elderly patients with mantle cell lymphoma. However, R-BAC is associated with significantly higher complete response rate, as well as prolonged 2-year progression-free survival compared to BR in this population.